Ensuring timely, efficient, and evidence-based additions to newborn screenings.

HB 1697 updates Washington's newborn screening program to ensure new conditions are added quickly and based on scientific evidence. It requires the state board of health to align the screening panel with the federal recommended list by 2027, and mandates feasibility reviews (assessing costs, funding, and timelines) before adding new conditions. The bill creates a dedicated revenue account for screening costs, ensuring fees collected from parents cover specialty clinics and outreach for conditions like sickle cell disease. It directly affects newborns, hospitals (which collect blood samples), and the Department of Health (which implements screenings and manages funds). The law aims to make the process more efficient while preserving public input for adding conditions outside the federal panel.